Investigating the role of isolevuglandins in high blood pressure and lupus
Official title: A Role of Isolevuglandins in Essential Hypertension and Systemic Lupus Erythematosus
Funded at Veterans Health Administration · NIH-10948077 · Data updated 2026-11-12
This study is looking at how certain molecules from fat breakdown might play a role in high blood pressure and lupus, and it's testing ways to block these molecules to help improve health for people with these conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Veterans Health Administration NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project start | October 1, 2021 |
| Project end | September 30, 2026 |
| Funding year | 2025 |
| NIH project number | 5IK2BX005376-04 |
| Project ID | NIH-10948077 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include veterans suffering from essential hypertension or systemic lupus erythematosus.
✕Less likely to help
Patients without hypertension or autoimmune conditions may not benefit from this research.
What this research studies
This research focuses on understanding how isolevuglandins, which are products of fatty acid oxidation, contribute to essential hypertension and systemic lupus erythematosus (SLE). The study examines how these molecules interact with proteins and activate immune cells, leading to hypertension and autoimmune responses. By using mouse models, the research aims to identify the mechanisms behind these conditions and explore potential treatments, such as isoLG scavengers, that could mitigate their effects.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that specifically target the underlying mechanisms of hypertension and lupus, improving patient outcomes.
How similar studies have gone: Previous studies have shown promising results in understanding the role of isolevuglandins in autoimmune diseases, suggesting that this approach may lead to significant advancements.
Where this research is happening
-
Veterans Health Administration
Nashville, United States Active
Researchers
- Principal investigator: Patrick, David — Veterans Health Administration
- Study coordinator: Patrick, David
Related research
Other NIH-funded projects on the same topics.
-
Oxidized fat byproducts linked to high blood pressure and lupus
This project looks at whether blocking harmful oxidized fat molecules called isolevuglandins can lower blood pressure and reduce autoimmune activity in people with hypertension and systemic lupus erythematosus.
-
Immunostimulatory short non-coding RNAs and lupus
A study in people with lupus looks at tiny RNA pieces that may spark inflammation, to understand if they drive disease activity.
-
Antiviral factors that limit HIV in people with SLE
Researchers at Howard University are studying how immune factors in people with lupus may help limit HIV infection.
-
Mechanistic clues about lupus from immune disorders
This grant looks at why certain immune disorders in people with genetic immune problems lead to lupus-like symptoms, by studying patients and mouse models.
-
Subjective thinking challenges in adults with lupus as they age
This grant aims to understand how lupus-related cognitive problems affect adults, especially older adults, and tests a real-time method to track daily fluctuations in those symptoms.
-
Mitochondrial targets of antibodies in lupus (SLE)
A Johns Hopkins-led study will identify which mitochondrial membrane proteins are targeted by autoantibodies in lupus patients to understand how these immune attacks fuel the disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.